Heron Therapeutics | HRTX - Assets


Heron Therapeutics reported $230.45M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
ANI Pharmaceuticals USD 1.57B 73.55M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Eisai JPY 1.52T 33.49B Sep/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 34.68B 33.44B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Veracyte USD 1.57B 86.89M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026